Drug intelligence / Profile preview

Oviderm

Development stage
Phase 4
Lead developer
Galenica
Modality
Small Molecules
Administration
Topical
01

Overview

Oviderm is a topical medicinal cream containing 25% propylene glycol, developed by the Swedish pharmaceutical company Galenica AB. It is specifically indicated for the treatment of dry skin (xerosis) associated with various dermatological conditions, including atopic dermatitis, psoriasis, and ichthyosis. The active ingredient, propylene glycol, functions as a potent humectant that increases the water-holding capacity of the stratum corneum, thereby improving skin hydration and reinforcing the skin's natural barrier function. At a 25% concentration, it also possesses mild antimicrobial properties, which can be beneficial in preventing secondary infections in compromised skin. Oviderm is formulated to provide effective moisturization while minimizing the irritation often associated with high-concentration propylene glycol products, making it suitable for the long-term management of chronic dry skin conditions.

Brand names
Oviderm
Other names
Propylene glycol 25% cream

Beyond the preview

Go deeper on Oviderm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oviderm.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call